Microsatellite Instability (MSI)

The defining genomic feature of MSI tumors is a dramatically elevated mutation rate, particularly in repetitive DNA tracts. This results in:

• Frameshift mutations: Insertions or deletions within coding microsatellites that disrupt gene function.
• High Tumor Mutational Burden (TMB): Often exceeding 10 mutations per megabase, generating a vast repertoire of neoantigens.
• Indel dominance: Unlike the single-nucleotide variant predominance in MSS tumors, MSI tumors are characterized by a high frequency of small insertions and deletions.

The high neoantigen load generated by frameshift mutations triggers a robust anti-tumor immune response, creating a distinct microenvironment:

• Dense lymphocytic infiltration: Tumor-infiltrating lymphocytes (TILs) and Crohn's-like peritumoral reaction are hallmark histologic features.
• Immune checkpoint upregulation: High expression of PD-1 and PD-L1, making these tumors exquisitely sensitive to immune checkpoint inhibitors like pembrolizumab.
• Tissue-agnostic biomarker: MSI-H status was the first FDA-approved pan-cancer biomarker for immunotherapy eligibility.

MSI arises from functional inactivation of the DNA mismatch repair (MMR) machinery, which can occur through two primary mechanisms:

• Sporadic (epigenetic): Biallelic somatic hypermethylation of the MLH1 promoter, accounting for ~80% of MSI-H colorectal cancers. Often associated with the BRAF V600E mutation and the CpG island methylator phenotype (CIMP).
• Hereditary (germline): Lynch syndrome, caused by germline mutations in MLH1, MSH2, MSH6, or PMS2, or by EPCAM deletions leading to MSH2 silencing. Requires confirmatory germline testing.

MSI-H tumors exhibit a characteristic clinical trajectory that diverges significantly from MSS counterparts:

• Favorable prognosis: In early-stage colorectal cancer, MSI-H status is an independent predictor of improved overall survival and reduced risk of distant metastasis.
• Resistance to 5-FU: Preclinical and clinical data suggest MSI-H colorectal tumors derive limited benefit from adjuvant fluoropyrimidine-based chemotherapy.
• Right-sided predominance: Sporadic MSI-H colorectal cancers are disproportionately located in the proximal colon and often present as poorly differentiated or mucinous histology.

Coding microsatellites within tumor suppressor genes are recurrently mutated in MSI tumors, generating predictable frameshift peptides:

• Target genes: TGFBR2, ACVR2, BAX, MSH3, and CASP5 are among the most frequently altered loci.
• Shared neoantigens: Because the same coding repeats are mutated across different patients, MSI tumors generate recurrent, shared immunogenic peptides that are absent from normal tissue.
• Vaccine targets: These predictable frameshift neoantigens are being exploited for the development of off-the-shelf cancer vaccines applicable across MSI-H patients.

MSI-H/dMMR status is the first pan-cancer tissue-agnostic biomarker approved by the FDA for checkpoint inhibitor therapy. Tumors with high microsatellite instability produce abundant neoantigens due to frameshift mutations in coding microsatellites, triggering robust immune recognition.

• Pembrolizumab approved for all MSI-H solid tumors regardless of tissue of origin
• Response rates of 30-50% in heavily pre-treated MSI-H patients
• Nivolumab + Ipilimumab combination shows enhanced efficacy in MSI-H colorectal cancer
• Testing is now standard-of-care for all stage IV colorectal and endometrial cancers

MSI testing serves as the primary universal screening tool for Lynch syndrome, the most common hereditary colorectal cancer predisposition. Loss of mismatch repair function in tumor tissue triggers reflex testing for germline mutations in MLH1, MSH2, MSH6, and PMS2 genes.

• Universal screening recommended for all newly diagnosed colorectal and endometrial cancers
• BRAF V600E mutation or MLH1 promoter hypermethylation testing excludes sporadic cases
• Identifies at-risk family members for cascade testing and surveillance
• Guides prophylactic surgery decisions and intensive screening protocols

MSI status provides independent prognostic information in stage II and III colorectal cancer. MSI-H tumors demonstrate a distinct clinical trajectory characterized by lower recurrence risk and differential response to fluoropyrimidine-based chemotherapy.

• Stage II MSI-H tumors have excellent prognosis with surgery alone
• MSI-H status predicts lack of benefit from 5-fluorouracil adjuvant therapy in stage II disease
• Stage III MSI-H tumors show improved overall survival compared to MSS counterparts
• Combined with TMB and immunoscore for multi-parametric risk stratification

Non-invasive MSI testing from cell-free DNA enables real-time monitoring without tissue biopsy. Machine learning algorithms analyze fragmentomic signatures and targeted sequencing of microsatellite loci to determine MSI status from blood.

• cfDNA-based MSI testing achieves >90% concordance with tissue-based methods
• Enables serial monitoring of MSI status during immunotherapy
• Detects acquired MSI as a resistance mechanism to targeted therapies
• Critical for patients with insufficient or inaccessible tumor tissue
• Fragment length analysis at microsatellite loci provides orthogonal validation

MSI-H occurs at varying frequencies across tumor types, with highest prevalence in endometrial, gastric, and colorectal cancers. NCCN and ESMO guidelines mandate MSI/MMR testing in multiple indications.

• Endometrial cancer: 20-30% MSI-H prevalence
• Gastric adenocarcinoma: 15-20% MSI-H
• Colorectal cancer: 15% overall, 5% in metastatic setting
• Testing methods include immunohistochemistry for MMR proteins and PCR-based microsatellite marker panels
• Next-generation sequencing assays now integrate MSI calling with comprehensive genomic profiling

Longitudinal MSI testing reveals dynamic changes in mismatch repair status during treatment. Acquired MSI emerges as a resistance mechanism to targeted therapies and can paradoxically sensitize tumors to immunotherapy.

• EGFR inhibitor resistance in colorectal cancer can arise through acquired MSI
• PARP inhibitor resistance in ovarian cancer associated with reversion mutations detectable via MSI
• Serial ctDNA monitoring captures clonal evolution of mismatch repair deficiency
• Guides sequential therapy decisions: targeted therapy → checkpoint inhibitor upon MSI-H conversion
• Heterogeneous MSI within tumors requires multi-region or liquid biopsy sampling